Pharma & Biotech Global Week in Review 3 Apr 09 from IP Think Tank

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

 
Highlight this week:

US: Third follow-on biologics bill, Promoting Innovation and Access to Life-Saving Medicine Act in 111th Congress; draws industry ire (Patent Docs) (Law360)

 
General

Brazil, India, EU: Seizures on drug consignments (Spicy IP)

Brazil: Widestrike GM cotton approved in Brazil (IP tango)

Canada: Access to drugs: Canada’s one licence solution (Afro-IP)

China: How to protect traditional Chinese medicine? (IP Dragon)

EU: Negative term SPC duration: A business intelligence consultant’s perspective (The SPC Blog)

EU: Q: When is medical use no use? A: When it’s in a patent claim. (IPKat)

US: Third follow-on biologics bill, Promoting Innovation and Access to Life-Saving Medicine Act in 111th Congress; draws industry ire (Patent Docs) (Law360)

US: CAFC: Anticipation of genus by prior art species in long list: In re Gleave (Hal Wegner) (Patent Docs)

US: Life Technologies, General Electric settle patent suit over DNA amplification kits (Law360)

 
Products

Concerta (Methylphenidate) – US: Delaware court rules Watson does not infringe patent related to generic version of Concerta and declares patent invalid (SmartBrief) (GenericsWeb)

Fosrenol (Lanthanum) – US: Shire files lawsuit against Natco Pharma for infringement of Fosrenol patents (GenericsWeb)

Gemzar (Gemcitabine) – UK: Expert witnesses – is there a better way?: Scinopharm Taiwan Ltd v Eli Lily & Co (PatLit)

Naglazyme (Galsulfase) – Brazil: Federal Court of the First Region orders government to supply unapproved drug Naglazyme (IP tango)

Plavix (Clopidogrel) – US: Bristol-Myers Squibb to pay $2.1 million to settle FTC claims it issues misleading statement about proposed Plavix patent deal with Apotex, violating court orders from earlier anti-trust cases (Law360)

Razadyne (Galantamine) – US: Johnson & Johnson units resolve patent infringement dispute with generic drug makers including Janssen over Razadyne (Law360)

 

 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: